Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Clones of infected cells arise early in HIV-infected individuals.

Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, Hughes SH.

JCI Insight. 2019 Jun 20;4(12). pii: 128432. doi: 10.1172/jci.insight.128432. eCollection 2019 Jun 20.

2.

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.

Boyer PL, Melody K, Smith SJ, Dunn LL, Kline C, Fischer DK, Dwivedi R, Clark P, Hughes SH, Ambrose Z.

J Virol. 2019 May 15;93(11). pii: e00224-19. doi: 10.1128/JVI.00224-19. Print 2019 Jun 1.

3.

Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration.

Achuthan V, Perreira JM, Sowd GA, Puray-Chavez M, McDougall WM, Paulucci-Holthauzen A, Wu X, Fadel HJ, Poeschla EM, Multani AS, Hughes SH, Sarafianos SG, Brass AL, Engelman AN.

Cell Host Microbe. 2018 Sep 12;24(3):392-404.e8. doi: 10.1016/j.chom.2018.08.002. Epub 2018 Aug 30.

PMID:
30173955
4.

Reprogramming human T cell function and specificity with non-viral genome targeting.

Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A.

Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.

5.

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01035-18. doi: 10.1128/AAC.01035-18. Print 2018 Sep.

6.

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7.

7.

Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase.

Boyer PL, Smith SJ, Zhao XZ, Das K, Gruber K, Arnold E, Burke TR Jr, Hughes SH.

J Virol. 2018 Jun 13;92(13). pii: e02203-17. doi: 10.1128/JVI.02203-17. Print 2018 Jul 1.

8.

Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs.

Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD.

Mol Cell. 2018 Feb 1;69(3):533. doi: 10.1016/j.molcel.2018.01.014. No abstract available.

9.

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.

Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.

10.

Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.

Bui JK, Sobolewski MD, Keele BF, Spindler J, Musick A, Wiegand A, Luke BT, Shao W, Hughes SH, Coffin JM, Kearney MF, Mellors JW.

PLoS Pathog. 2017 Mar 22;13(3):e1006283. doi: 10.1371/journal.ppat.1006283. eCollection 2017 Mar.

11.

Drug resistant integrase mutants cause aberrant HIV integrations.

Varadarajan J, McWilliams MJ, Mott BT, Thomas CJ, Smith SJ, Hughes SH.

Retrovirology. 2016 Sep 29;13(1):71.

12.

Multiple Origins of Virus Persistence during Natural Control of HIV Infection.

Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal A, Bunis D, Nganou-Makamdop K, Lee JS, Migueles SA, Koup RA, Connors M, Moir S, Schacker T, Maldarelli F, Hughes SH, Deeks SG, Douek DC.

Cell. 2016 Aug 11;166(4):1004-1015. doi: 10.1016/j.cell.2016.06.039. Epub 2016 Jul 21.

13.

Retrovirus Integration Database (RID): a public database for retroviral insertion sites into host genomes.

Shao W, Shan J, Kearney MF, Wu X, Maldarelli F, Mellors JW, Luke B, Coffin JM, Hughes SH.

Retrovirology. 2016 Jul 4;13(1):47. doi: 10.1186/s12977-016-0277-6.

14.

Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y.

Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1.

15.

Creating Individualized Symptom Management Goals and Strategies for Cancer-Related Fatigue for Patients With Recurrent Ovarian Cancer.

Hagan TL, Arida JA, Hughes SH, Donovan HS.

Cancer Nurs. 2017 Jul/Aug;40(4):305-313. doi: 10.1097/NCC.0000000000000407.

16.

What Integration Sites Tell Us about HIV Persistence.

Hughes SH, Coffin JM.

Cell Host Microbe. 2016 May 11;19(5):588-98. doi: 10.1016/j.chom.2016.04.010. Review.

17.

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.

Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):485-91. doi: 10.1097/QAI.0000000000001031.

18.

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.

Smith SJ, Pauly GT, Akram A, Melody K, Rai G, Maloney DJ, Ambrose Z, Thomas CJ, Schneider JT, Hughes SH.

Retrovirology. 2016 Feb 16;13:11. doi: 10.1186/s12977-016-0244-2.

19.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

20.

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.

Zhao XZ, Smith SJ, Maskell DP, Metifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

ACS Chem Biol. 2016 Apr 15;11(4):1074-81. doi: 10.1021/acschembio.5b00948. Epub 2016 Feb 5.

21.

LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes.

Singh PK, Plumb MR, Ferris AL, Iben JR, Wu X, Fadel HJ, Luke BT, Esnault C, Poeschla EM, Hughes SH, Kvaratskhelia M, Levin HL.

Genes Dev. 2015 Nov 1;29(21):2287-97. doi: 10.1101/gad.267609.115.

22.

Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.

Boyer PL, Das K, Arnold E, Hughes SH.

Antimicrob Agents Chemother. 2015 Dec;59(12):7184-96. doi: 10.1128/AAC.05069-14. Epub 2015 Aug 31.

23.

6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors.

Zhao XZ, Metifiot M, Smith SJ, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Curr Top Med Chem. 2016;16(4):435-40. Review.

PMID:
26268341
24.

Reverse Transcription of Retroviruses and LTR Retrotransposons.

Hughes SH.

Microbiol Spectr. 2015 Apr;3(2):MDNA3-0027-2014. doi: 10.1128/microbiolspec.MDNA3-0027-2014. Review.

PMID:
26104704
25.

Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients.

Dunn LL, Boyer PL, McWilliams MJ, Smith SJ, Hughes SH.

Virology. 2015 Oct;484:127-35. doi: 10.1016/j.virol.2015.05.020. Epub 2015 Jun 18.

26.

Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs.

Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD.

Mol Cell. 2015 Jul 2;59(1):89-103. doi: 10.1016/j.molcel.2015.05.017. Epub 2015 Jun 11. Erratum in: Mol Cell. 2018 Feb 1;69(3):533.

27.

The Integrator complex controls the termination of transcription at diverse classes of gene targets.

Skaar JR, Ferris AL, Wu X, Saraf A, Khanna KK, Florens L, Washburn MP, Hughes SH, Pagano M.

Cell Res. 2015 Mar;25(3):288-305. doi: 10.1038/cr.2015.19. Epub 2015 Feb 13.

28.

A mouse strain defective in both T cells and NK cells has enhanced sensitivity to tumor induction by plasmid DNA expressing both activated H-Ras and c-Myc.

Sheng-Fowler L, Tu W, Fu H, Murata H, Lanning L, Foseh G, Macauley J, Blair D, Hughes SH, Coffin JM, Lewis AM Jr, Peden K.

PLoS One. 2014 Oct 10;9(10):e108926. doi: 10.1371/journal.pone.0108926. eCollection 2014.

29.

HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells.

Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH.

Science. 2014 Jul 11;345(6193):179-83. doi: 10.1126/science.1254194. Epub 2014 Jun 26.

30.

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.

Zhao XZ, Smith SJ, Métifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Jun 26;57(12):5190-202. doi: 10.1021/jm5001908. Epub 2014 Jun 16. Erratum in: J Med Chem. 2014 Aug 14;57(15):6885.

31.

Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.

Abram ME, Ferris AL, Das K, Quinoñes O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH.

J Virol. 2014 Jul;88(13):7589-601. doi: 10.1128/JVI.00302-14. Epub 2014 Apr 23.

32.

Rapid screening of HIV reverse transcriptase and integrase inhibitors.

Smith SJ, Hughes SH.

J Vis Exp. 2014 Apr 9;(86). doi: 10.3791/51400.

33.

Enhancers are major targets for murine leukemia virus vector integration.

De Ravin SS, Su L, Theobald N, Choi U, Macpherson JL, Poidinger M, Symonds G, Pond SM, Ferris AL, Hughes SH, Malech HL, Wu X.

J Virol. 2014 Apr;88(8):4504-13. doi: 10.1128/JVI.00011-14. Epub 2014 Feb 5.

34.

False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector.

De Ravin SS, Gray JT, Throm RE, Spindler J, Kearney M, Wu X, Coffin JM, Hughes SH, Malderelli F, Sorrentino BP, Malech HL.

Mol Ther. 2014 Feb;22(2):244-245. doi: 10.1038/mt.2013.296. No abstract available.

35.

Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Feb 27;57(4):1573-82. doi: 10.1021/jm401902n. Epub 2014 Feb 10.

36.

Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles.

Ivetac A, Swift SE, Boyer PL, Diaz A, Naughton J, Young JA, Hughes SH, McCammon JA.

Chem Biol Drug Des. 2014 May;83(5):521-31. doi: 10.1111/cbdd.12277. Epub 2014 Mar 24.

37.

Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7.

38.

Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.

Varadarajan J, McWilliams MJ, Hughes SH.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14747-52. doi: 10.1073/pnas.1305066110. Epub 2013 Aug 19.

39.

Mutations in HIV-1 reverse transcriptase cause misfolding and miscleavage by the viral protease.

Dunn LL, Boyer PL, Clark PK, Hughes SH.

Virology. 2013 Sep;444(1-2):241-9. doi: 10.1016/j.virol.2013.06.017. Epub 2013 Jul 11.

40.

A homology model of HIV-1 integrase and analysis of mutations designed to test the model.

Johnson BC, Métifiot M, Ferris A, Pommier Y, Hughes SH.

J Mol Biol. 2013 Jun 26;425(12):2133-46. doi: 10.1016/j.jmb.2013.03.027. Epub 2013 Mar 27.

PMID:
23542006
41.

H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation.

Lauberth SM, Nakayama T, Wu X, Ferris AL, Tang Z, Hughes SH, Roeder RG.

Cell. 2013 Feb 28;152(5):1021-36. doi: 10.1016/j.cell.2013.01.052.

42.

Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase.

Elleder D, Baiga TJ, Russell RL, Naughton JA, Hughes SH, Noel JP, Young JA.

Virol J. 2012 Dec 11;9:305. doi: 10.1186/1743-422X-9-305.

43.

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.

Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH.

Retrovirology. 2012 Dec 5;9:99. doi: 10.1186/1742-4690-9-99.

44.

6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.

Zhao XZ, Maddali K, Smith SJ, Métifiot M, Johnson BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7309-13. doi: 10.1016/j.bmcl.2012.10.088. Epub 2012 Oct 27.

45.

Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.

Koh Y, Wu X, Ferris AL, Matreyek KA, Smith SJ, Lee K, KewalRamani VN, Hughes SH, Engelman A.

J Virol. 2013 Jan;87(1):648-58. doi: 10.1128/JVI.01148-12. Epub 2012 Oct 24.

46.

Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.

Métifiot M, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR Jr, Hughes SH, Cherepanov P, Pommier Y.

ACS Chem Biol. 2013 Jan 18;8(1):209-17. doi: 10.1021/cb300471n. Epub 2012 Dec 24.

47.

HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor.

Wang H, Jurado KA, Wu X, Shun MC, Li X, Ferris AL, Smith SJ, Patel PA, Fuchs JR, Cherepanov P, Kvaratskhelia M, Hughes SH, Engelman A.

Nucleic Acids Res. 2012 Dec;40(22):11518-30. doi: 10.1093/nar/gks913. Epub 2012 Oct 5.

48.

HIV-1 reverse transcription.

Hu WS, Hughes SH.

Cold Spring Harb Perspect Med. 2012 Oct 1;2(10). pii: a006882. doi: 10.1101/cshperspect.a006882. Review.

49.

HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.

Boyer PL, Clark PK, Hughes SH.

J Virol. 2012 May;86(10):5885-94. doi: 10.1128/JVI.06597-11. Epub 2012 Mar 21.

50.

Multiple sources of contamination in samples from patients reported to have XMRV infection.

Kearney MF, Spindler J, Wiegand A, Shao W, Anderson EM, Maldarelli F, Ruscetti FW, Mellors JW, Hughes SH, Le Grice SF, Coffin JM.

PLoS One. 2012;7(2):e30889. doi: 10.1371/journal.pone.0030889. Epub 2012 Feb 20.

Supplemental Content

Loading ...
Support Center